Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCG vaccine - Vakzine Projekt Management/Serum Institute of India

Drug Profile

BCG vaccine - Vakzine Projekt Management/Serum Institute of India

Alternative Names: BCG VPM 1002; BCG-vaccine-Vakzine-Projekt-Management; rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BC

Latest Information Update: 30 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Institute for Infection Biology
  • Developer Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
  • Class Tuberculosis vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections; Respiratory tract infections
  • Phase II/III Tuberculosis
  • Phase I/II Bladder cancer

Most Recent Events

  • 08 Sep 2020 Serum Institute of India withdraws a phase III trial for COVID-2019 infections (Prevention) in Australia (Intradermal) due to commercial reasons (ACTRN12620000707965)
  • 03 Sep 2020 Vakzine Projekt Management terminates phase III clinical trials in COVID-2019 infections (Prevention) in Germany (Intradermal) due to unspecified reasons (EudraCT2020-001376-15) (NCT04387409)
  • 29 Jun 2020 Serum Institute of India plans a phase III trial for COVID-2019 infections (Prevention) in Australia (Intradermal) (ACTRN12620000707965)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top